logo

For the Inventor, By the Inventor

Chester, NJ, United States of America

Galen W Radebaugh

This inventor holds 21 USPTO granted patents and 1 EPO patent, primarily in Pharmaceutical Formulations. Top assignees: Wyeth, Warner-Lambert Company, Mcneil Ab. Active years: 1989-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Galen W Radebaugh. Retrieved from https://idiyas.com/inventor/galen-w-radebaugh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 21

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.3

ph-index = 11

Forward Citations = 735(Granted Patents)


Location History:

  • Maple Glen, PA (US) (1989 - 1995)
  • Chester, NJ (US) (1991 - 2017)

Company Filing History:

goldMedal7 out of 1,309 
 
Wyeth
 patents
silverMedal6 out of 2,538 
 
Warner-Lambert Company
 patents
bronzeMedal4 out of 189 
 
Mcneil Ab
 patents
4. 3 out of 798 
 
Mcneil-Ppc, Inc.
 patents
5. 1 out of 1 
 
Mcneil Consumer Products Company
 patent

Years Active: 1989-2017

Loading Chart...
Loading Chart...
Areas of Expertise:
Peripheral Opioid Receptor Antagonists
Sustained Release Matrix
Thrombin Preparation
Cognition Activator
Taste Masking
Antibacterial Complexes
Cholinergic Compounds
Oral Formulation
Pharmaceutical Process
Ultra-Pure Preparation
Acetaminophen Formulation
Iburprofen Matrix
21 patents (USPTO):Explore Patents
1. 9724343 - Peripheral opioid receptor antagonists and uses thereof (2017-08-08),
2. 9492445 - Peripheral opioid receptor antagonists and uses thereof (2016-11-15),
3. 9180125 - Peripheral opioid receptor antagonists and uses thereof (2015-11-10),
4. 8822490 - Peripheral opioid receptor antagonists and uses thereof (2014-09-02),
5. 8455644 - Peripheral opioid receptor antagonists and uses thereof (2013-06-04),
6. 8420663 - Peripheral opioid receptor antagonists and uses thereof (2013-04-16),
7. 8247425 - Peripheral opioid receptor antagonists and uses thereof (2012-08-21),
8. 5525498 - Process for preparing an ultra-pure thrombin preparation (1996-06-11),
9. 5462747 - Pharmaceutical sustained release matrix (1995-10-31),
10. 5424301 - Starch stabilized o-substituted tetrahydropyridine oxime cholinergic (1995-06-13),
11. 5397704 - Ultra-pure thrombin preparation (1995-03-14),
12. 5362860 - Neutral stabilization complex for CI-979 HCl, a cognition activator (1994-11-08),
13. 5290794 - Soluble calcium lactate antibacterial complexes as non-irritating (1994-03-01),
14. 5281528 - Process for purified thromboplastin for ultra-pure thrombin preparation (1994-01-25),
15. 5200193 - Pharmaceutical sustained release matrix and process (1993-04-06),

Title: Unveiling the Inventive Journey of Galen W Radebaugh

Introduction:

Galen W Radebaugh, a prolific inventor based in Chester, NJ, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 21 patents.

Latest Patents:

Among his latest patents is the groundbreaking innovation titled "Peripheral opioid receptor antagonists and uses thereof", introducing a novel compound of formula I. This invention showcases Radebaugh's commitment to advancing medical solutions through cutting-edge research.

Career Highlights:

Having worked with reputable companies like Wyeth and Warner-Lambert Company, Radebaugh has honed his expertise in pharmaceutical research and development. His innovative spirit and dedication to scientific advancement have led to the successful creation and commercialization of numerous patented inventions.

Collaborations:

Throughout his career, Radebaugh has collaborated with esteemed colleagues such as Robert Glinecke and Nataliya Bazhina. These partnerships have fostered a dynamic environment for brainstorming, experimentation, and the realization of groundbreaking ideas in the pharmaceutical industry.

Conclusion:

In conclusion, Galen W Radebaugh's journey as an inventor exemplifies a steadfast pursuit of innovation and excellence. His patents stand as a testament to his unwavering commitment to pushing the boundaries of scientific discovery in the pharmaceutical realm, ultimately benefiting society as a whole.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…